Preview

Rational Pharmacotherapy in Cardiology

Advanced search

IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE

https://doi.org/10.20996/1819-6446-2018-14-2-176-183

Full Text:

Abstract

Background. Levosimendan infusion can be used in the treatment of patients with acute decompensated heart failure (ADHF) with a reduction in cardiac output and signs of severe congestion/pulmonary edema.

Aim. To study impact of levosimendan on renal function in patients with ADHF with reduced systolic function.

Material and methods. The study was a prospective, randomized trial. We enrolled 30 men (age 62.5 [55.8-69.3] years) hospitalized with ADHF with reduced systolic function (left ventricular ejection fraction <40%), increased level of brain natriuretic peptide (BNP>500 pg/mL) and systolic blood pressure >125 mmHg. All patients were randomized into 2 groups of 15 people each. In the first group, the patients received an intravenous infusion of levosimendan 0.1 μg/kg/min for 24 hour added to standard therapy. The second group received standard therapy.

Results. 24-hour levosimendan infusion significantly increased the glomerular filtration rate levels from 65.4 [45.2-99.2] mL/min/1.73m2 at baseline to 79.0 [66.3-93.1] mL/min/1.73m2 at discharge (p= 0.011), greatly decreased serum creatinine from 1.17 [0.90-1.55] mg/dL at baseline to 1.01 [0.89-1.14] mg/dL at discharge (p = 0.009) and blood urea nitrogen and at the same time improved renal blood flow in patients with ADHF while there were no clinically significant changes in the studied parameters in the standard therapy group.

Conclusion. Levosimendan had a positive effect on renal function in patients with ADHF with reduced systolic function.

About the Authors

M. V. Lediakhova
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Maria V. Lediakhova – MD, Postgraduate Student, Department of Myocardial Diseases and Heart Failure

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



S. N. Nasonova
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Svetlana N. Nasonova – MD, PhD, Senior Researcher, Department of Myocardial Diseases and Heart Failure

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



I. V. Zhirov
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Igor V. Zhirov – MD, PhD, Leading Researcher, Department of Myocardial Diseases and Heart Failure

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



M. V. Andreevskaya
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Marina V. Andreevskaya – MD, PhD, Junior Researcher, Department of Ultrasound Research Methods

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



R. M. Bogieva
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Roxana M. Bogieva – MD, PhD, Doctor, Department of Ultrasound Diagnostics

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



T. M. Uskach
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Tatyana M. Uskach – MD, PhD, Head of 8th Cardiology Department

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



M. A. Saidova
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Marina A. Saidova – MD, PhD, Professor, Head of Department of Ultrasound Research Methods

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



V. P. Masenko
Institute of Cardiology named after A.L. Myasnikov; National Medical Research Center of Cardiology
Russian Federation

Valerii P. Masenko – MD, PhD, Professor, Head of Department of Neurohumoral and Immunological Research

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



S. N. Tereshchenko
Institute of Cardiology named after A.L. Myasnikov$ National Medical Research Center of Cardiology
Russian Federation

Sergey N. Tereshchenko – MD, PhD, Professor, Head of Department of Myocardial Diseases and Heart Failure, Institute of Cardiology named after A.L. Myasnikov, First Deputy General Director, National Medical Research Center of Cardiology

Tretya Cherepkovskaya ul. 15a, Moscow, 121552



References

1. Tereschenko S.N., Zhirov I.V., Nasonov aS.N., et al. Acute Decompensated Heart Failure: What We Know in 2016. Lechebnoe Delo. 2016;2:4-13. (In Russ.)

2. Vatutin N.T., Taradin G.G., Kolesnikov V. S., et al. Cardiorenal syndrome in intensive care. RussianHeartFailureJournal. 2016;17(1):47-55. (In Russ.)

3. Pollesello P, Papp Z, Papp JG. Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol. 2016;203:543-8. doi: 10.1016/j.ijcard.2015.10.240.

4. Pathak A, Lebrin M, VaccaroA et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotectiveeffects. J Clin Pharm Ther. 2013;38:341-9. doi: 10.1111/jcpt.12067.

5. Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016;222:303-12. doi: 10.1016/j.ijcard.2016.07.202.

6. Caimmi PP, Molinari C. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011;39:59-67. doi: 10.1016/j.ejcts.2010.11.044.

7. Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol. 2007;150(7):851-61. doi:10.1038/sj.bjp.0707157.

8. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50:257-63. doi: 10.1097/FJC.0b013e3180986230.

9. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431-5. doi:10.1007/s10557-007-6066-7.

10. Сlinical guidelines for the diagnosis and treatment of chronic and acute heart failure. Kardiologicheskij Vestnik. 2016;2:3-33. (In Russ.)

11. A clinical guideline for management of patients with acute heart failure at pre-hospital and hospital stages of care delivery (part 2). Emergency Cardiology. 2017;13(1):34-59. (In Russ.)

12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.

13. Packer M, Colucci W, Fisher L et al. REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1:103-111. doi: 10.1016/j.jchf.2012.12.004.

14. Lilleberg J, Laine M, Palkama T et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75-82. doi: 10.1016/j.ejheart.2006.04.012.

15. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on betablockers in SURVIVE. Eur J Heart Fail. 2009;11:304-311. doi: 10.1093/eurjhf/hfn045.

16. National clinical guidelines (OSSN, RKO, RNMOT) on diagnostics and treatment of chronic heart failure (4th edition). Russian Heart Failure Journal. 2013;81(7):379-472. (In Russ.)

17. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):147-239. doi: 10.1016/j.jacc.2013.05.019.

18. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure. 2015;17(6):544-58. doi: 10.1002/ejhf.289.

19. A clinical guideline for management of patients with acute heart failure at pre-hospital and hospital stages of care delivery (part 1). Emergency Cardiology. 2016;12(4):33-61. (In Russ.)

20. A clinical guideline for management of patients with acute heart failure at pre-hospital and hospital stages of care delivery (part 3). Emergency Cardiology. 2017;14(2):43-64. (In Russ.)

21. Poelzl G, Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33:368-373. doi: 10.1007/s00059-008-3051-2.

22. Russ MA, Prondzinsky R, Carter JM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37:3017-23. doi: 10.1097/CCM.0b013e3181b0314a.

23. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328-35. doi: 10.1097/CCM.0b013e31828e946a.

24. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581-90. doi: 10.1007/s10557-013-6485-6.

25. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. AJP-Renal Physiol. 2006;290(6):1453-62. doi:10.1152/ajprenal.00485.2005.

26. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360:196-202. doi: 10.1016/S0140-6736(02)09455-2.

27. Hou ZQ, Sun ZX, Su CY, Tan H et al. Shang Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31:108-114. doi: 10.1111/1755-5922.12001.

28. Zorlu A, Yucel H, Yontar OC, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537-43. doi: 10.1590/S0066782X2012005000048.

29. Rafouli-Stergiou P, Parissis JT, Farmakis D et al. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. J Cardiovasc Med (Hagerstown). 2015;1-3. doi: 10.2459/JCM.0000000000000244.


For citation:


Lediakhova M.V., Nasonova S.N., Zhirov I.V., Andreevskaya M.V., Bogieva R.M., Uskach T.M., Saidova M.A., Masenko V.P., Tereshchenko S.N. IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2018;14(2):176-183. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-2-176-183

Views: 208


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)